Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of April 2022. The filing, dated April 13, 2022, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative data.
Material Changes
The filing does not detail material changes versus prior periods within the text provided. The primary content is the announcement of the press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Specific guidance, outlook, management commentary, risks, contingencies, or unusual items are not described in the body of this Form 6-K. These details are contained within the referenced press release (Exhibit 99.1), the text of which is not included in the input.
Key Facts for Investor Verification
- Verify the content of the press release dated April 13, 2022, attached as Exhibit 99.1, as this filing incorporates it by reference.
- Confirm the specific operational or clinical updates announced in the referenced press release, as the Form 6-K itself contains no narrative details.
- Note that this filing is signed by Tim Dyer, Chief Executive Officer.